Tissue | Expression Dynamics | Abbreviation |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007030232 | Oral cavity | NEOLP | regulation of stress-activated protein kinase signaling cascade | 37/2005 | 195/18723 | 3.90e-04 | 3.63e-03 | 37 |
GO:004563724 | Oral cavity | NEOLP | regulation of myeloid cell differentiation | 39/2005 | 210/18723 | 4.32e-04 | 3.93e-03 | 39 |
GO:000268723 | Oral cavity | NEOLP | positive regulation of leukocyte migration | 28/2005 | 135/18723 | 4.45e-04 | 4.01e-03 | 28 |
GO:004563923 | Oral cavity | NEOLP | positive regulation of myeloid cell differentiation | 23/2005 | 103/18723 | 4.71e-04 | 4.21e-03 | 23 |
GO:190136131 | Oral cavity | NEOLP | organic cyclic compound catabolic process | 77/2005 | 495/18723 | 4.96e-04 | 4.40e-03 | 77 |
GO:190435631 | Oral cavity | NEOLP | regulation of telomere maintenance via telomere lengthening | 16/2005 | 61/18723 | 5.23e-04 | 4.61e-03 | 16 |
GO:006034821 | Oral cavity | NEOLP | bone development | 38/2005 | 205/18723 | 5.28e-04 | 4.64e-03 | 38 |
GO:004886316 | Oral cavity | NEOLP | stem cell differentiation | 38/2005 | 206/18723 | 5.82e-04 | 5.05e-03 | 38 |
GO:000181923 | Oral cavity | NEOLP | positive regulation of cytokine production | 73/2005 | 467/18723 | 5.95e-04 | 5.14e-03 | 73 |
GO:004825514 | Oral cavity | NEOLP | mRNA stabilization | 15/2005 | 56/18723 | 6.08e-04 | 5.23e-03 | 15 |
GO:007121424 | Oral cavity | NEOLP | cellular response to abiotic stimulus | 55/2005 | 331/18723 | 6.38e-04 | 5.43e-03 | 55 |
GO:010400424 | Oral cavity | NEOLP | cellular response to environmental stimulus | 55/2005 | 331/18723 | 6.38e-04 | 5.43e-03 | 55 |
GO:000756531 | Oral cavity | NEOLP | female pregnancy | 36/2005 | 193/18723 | 6.47e-04 | 5.47e-03 | 36 |
GO:007147831 | Oral cavity | NEOLP | cellular response to radiation | 35/2005 | 186/18723 | 6.47e-04 | 5.47e-03 | 35 |
GO:003220031 | Oral cavity | NEOLP | telomere organization | 31/2005 | 159/18723 | 6.95e-04 | 5.76e-03 | 31 |
GO:006053813 | Oral cavity | NEOLP | skeletal muscle organ development | 32/2005 | 166/18723 | 7.05e-04 | 5.81e-03 | 32 |
GO:200027832 | Oral cavity | NEOLP | regulation of DNA biosynthetic process | 23/2005 | 106/18723 | 7.22e-04 | 5.93e-03 | 23 |
GO:004592722 | Oral cavity | NEOLP | positive regulation of growth | 45/2005 | 259/18723 | 7.42e-04 | 6.05e-03 | 45 |
GO:000627831 | Oral cavity | NEOLP | RNA-dependent DNA biosynthetic process | 18/2005 | 75/18723 | 7.69e-04 | 6.20e-03 | 18 |
GO:007122231 | Oral cavity | NEOLP | cellular response to lipopolysaccharide | 38/2005 | 209/18723 | 7.74e-04 | 6.23e-03 | 38 |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
MAPK1 | CD8TEXINT | Colorectum | AD | ITGA1,YPEL1,UBASH3B, etc. | 2.57e-01 | |
MAPK1 | CD8TEREX | Colorectum | AD | ITGA1,YPEL1,UBASH3B, etc. | 2.43e-01 | |
MAPK1 | MAIT | Colorectum | ADJ | ITGA1,YPEL1,UBASH3B, etc. | 1.38e-01 | |
MAPK1 | CD8TEREX | Colorectum | ADJ | ITGA1,YPEL1,UBASH3B, etc. | 1.84e-01 | |
MAPK1 | CD8TEXINT | Colorectum | ADJ | ITGA1,YPEL1,UBASH3B, etc. | 1.00e-01 | |
MAPK1 | CD8TEREX | Colorectum | CRC | ITGA1,YPEL1,UBASH3B, etc. | 6.38e-02 | |
MAPK1 | TREG | Colorectum | CRC | ITGA1,YPEL1,UBASH3B, etc. | 1.20e-01 | |
MAPK1 | TH17 | Colorectum | FAP | ITGA1,YPEL1,UBASH3B, etc. | 8.39e-02 | |
MAPK1 | CD8TEREX | Colorectum | FAP | ITGA1,YPEL1,UBASH3B, etc. | 2.37e-01 | |
MAPK1 | MAIT | Colorectum | FAP | ITGA1,YPEL1,UBASH3B, etc. | 1.13e-01 | |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAPK1 | SNV | Missense_Mutation | | c.241G>A | p.Glu81Lys | p.E81K | P28482 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-BH-A0B5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | CR |
MAPK1 | SNV | Missense_Mutation | rs747124623 | c.994G>A | p.Asp332Asn | p.D332N | P28482 | protein_coding | deleterious(0.03) | benign(0.001) | TCGA-E2-A14N-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
MAPK1 | insertion | Frame_Shift_Ins | novel | c.1024_1025insTTGTGAGCCAAGGTAGAAGCAGTTGCTGGGGAGATGC | p.Lys342IlefsTer20 | p.K342Ifs*20 | P28482 | protein_coding | | | TCGA-AN-A03Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAPK1 | SNV | Missense_Mutation | | c.964N>A | p.Glu322Lys | p.E322K | P28482 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-C5-A1BI-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
MAPK1 | SNV | Missense_Mutation | | c.964G>A | p.Glu322Lys | p.E322K | P28482 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD |
MAPK1 | SNV | Missense_Mutation | | c.961G>A | p.Asp321Asn | p.D321N | P28482 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-DG-A2KL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
MAPK1 | SNV | Missense_Mutation | | c.964N>A | p.Glu322Lys | p.E322K | P28482 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-DS-A0VN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
MAPK1 | SNV | Missense_Mutation | | c.964N>A | p.Glu322Lys | p.E322K | P28482 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-EA-A1QS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
MAPK1 | SNV | Missense_Mutation | | c.404G>A | p.Arg135Lys | p.R135K | P28482 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-EA-A3HT-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
MAPK1 | SNV | Missense_Mutation | | c.964G>A | p.Glu322Lys | p.E322K | P28482 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-EA-A5ZD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | PROGESTERONE | PROGESTERONE | |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | SPINASAPONIN A METHYL ESTER | SPINASAPONIN A METHYL ESTER | 20951582 |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | DIHYDROGAMBOGIC ACID | DIHYDROGAMBOGIC ACID | |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | TREQUINSIN HYDROCHLORIDE | TREQUINSIN HYDROCHLORIDE | |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | BENZOTHIAZOL-2-YLAMINE | CHEMBL329785 | 22982122 |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | PHENETHYLISOTHIOCYANATE | PHENETHYLISOTHIOCYANATE | 22607231 |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | GENTIAN VIOLET | GENTIAN VIOLET | |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | MITOXANTRONE DIHYDROCHLORIDE | MITOXANTRONE HYDROCHLORIDE | |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | DAUNORUBICIN HYDROCHLORIDE | DAUNORUBICIN HYDROCHLORIDE | |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | ZM-449829 | CHEMBL154580 | |